You are viewing: Europe Immune Repertoire Sequencing Market analysis

The Europe Immune Repertoire Sequencing Market was valued at $62 Million in 2025 and projected to reach to $99.5 Million by 2030, representing a compound annual growth rate of 9.9%. Europe's immune repertoire sequencing market is positioned for sustained expansion, driven by robust healthcare infrastructure, significant R&D investments, and regulatory support for precision medicine initiatives.

Europe Immune Repertoire Sequencing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Immune Repertoire Sequencing Market Trends and Insights

  • This 9.9% compound annual growth rate reflects Europe's strong investment in precision medicine and immunological research infrastructure.
  • Europe is leveraging advanced sequencing technologies to enhance diagnostic capabilities and accelerate immunotherapy development across oncology, infectious disease, and autoimmune disorder applications. The European market benefits from well-established healthcare systems, substantial R&D funding, and regulatory frameworks that support innovation in genomic medicine.
  • Europe's commitment to personalized healthcare and immunological profiling is driving adoption among academic institutions, clinical laboratories, and biopharmaceutical companies.
  • By 2030, Europe is expected to consolidate its position as a leading region for immune repertoire sequencing, supported by increasing clinical validation studies and integration into routine diagnostic workflows..

Key Market Statistics

  • CAGR (2025-2030) 9.9% CAGR
  • Market Size, 2025 ~USD 62 Million
  • Forecast, 2030 ~USD 99.5 Million
  • Geography Europe

Europe Immune Repertoire Sequencing Market Overview

Strong Regional Valuation :

Europe's immune repertoire sequencing market is valued at $62.0 million in 2025, demonstrating significant investment in advanced immunological diagnostics and precision medicine infrastructure across the continent.

Robust Growth Trajectory :

With a 9.9% CAGR through 2030, Europe outpaces the global growth rate of 9.6%, reflecting accelerated adoption of sequencing technologies in clinical and research settings.

Leadership in Precision Medicine :

European nations are leveraging cutting-edge sequencing technologies to enhance diagnostic capabilities, accelerate immunological research, and support personalized treatment strategies across oncology and immunotherapy domains.

Forecast Expansion to $99.5M :

By 2030, the European market is projected to reach $99.5 million, representing a 60.5% increase from 2025 and underscoring sustained confidence in immune repertoire sequencing applications.

Europe Immune Repertoire Sequencing Market Dynamics

  • Leading European nations are integrating immune sequencing into clinical diagnostics, particularly for cancer immunotherapy and infectious disease monitoring, creating strong demand across academic medical centers and commercial laboratories. The market's 9.9% CAGR reflects Europe's commitment to advancing immunological research and personalized treatment paradigms.
  • Increasing collaboration between research institutions and diagnostic companies, coupled with growing reimbursement recognition, will further accelerate adoption.
  • By 2030, Europe is expected to solidify its position as a key hub for immune repertoire sequencing innovation and clinical implementation..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Europe's immune repertoire sequencing market is valued at $62.0 million in 2025 and projected to reach $99.5 million by 2030, representing a 9.9% CAGR.
    • Europe's advanced healthcare infrastructure and substantial R&D investment are accelerating adoption of immune repertoire sequencing across clinical and research settings.
    • Europe is driving innovation in personalized immunotherapy and precision diagnostics, positioning the region as a leader in immunological profiling technologies.
    • By 2030, Europe's market expansion will be supported by regulatory approval, clinical validation, and integration into standard diagnostic protocols across major healthcare systems.

    Immune Repertoire Sequencing Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment TCR KITS (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.6% from 2025 to 2030
    Largest Segment ASSAY KITS & REAGENTS (Product)
    Market Size Base Year (Billions) ~USD 0.35 (2025)
    Revenue Forecast (Billions) ~USD 0.56 (2030)
    Segments Covered Product, Type

    Europe Immune Repertoire Sequencing Market Report Segmentation

    2 segment dimensions are covered across the global market.

    By Product

    • Assay Kits & Reagents
    • Instruments & Software

    By Type

    • Bcr Kits
    • Other Assay Kits & Reagents
    • Tcr Kits

    REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES2.921.71.61.61.82.12.810.5
    OTHER END USERS1.71.210.90.911.21.59.2
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES4.332.52.42.42.73.24.210.6
    TOTAL96.25.24.84.95.56.58.410.3

    EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES28.228.531.234.137.441.145.3509.9
    OTHER END USERS17.517.619.120.822.624.626.929.49
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES25.72628.531.334.437.841.746.110.1
    TOTAL71.472.278.886.194.4103.6113.9125.59.8

    Target Audience

    • Diagnostic & Sequencing Companies : European and global diagnostic firms need detailed market intelligence to assess expansion opportunities, competitive positioning, and revenue potential within Europe's high-growth immune sequencing segment.
    • Pharmaceutical & Biotech Firms : Immunotherapy and precision medicine companies require European market data to identify clinical adoption trends, partnership opportunities, and companion diagnostic integration strategies.
    • Healthcare Investors & PE Firms : Investment professionals evaluating European healthcare technology opportunities need market sizing, growth projections, and competitive analysis to support due diligence and portfolio decisions.
    • Academic & Research Institutions : European research centers and medical universities require market insights to understand commercialization pathways, funding trends, and collaboration opportunities in immune sequencing innovation.
    • Healthcare Policy & Regulatory Bodies : European health authorities and policy makers need market intelligence to inform reimbursement decisions, regulatory frameworks, and healthcare technology adoption strategies.

    Key Companies in the Europe Immune Repertoire Sequencing Market

    CompanyHQOwnershipStrongest segments
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PACBIOUnited StatesPublic CompanyLong-read sequencing instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read sequencing (Onso and related consumables),
    OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION (2/24/48) instruments and consumables,MinION Mk 1D and related consumables,GridION / GridION Q systems and consumables,
    10X GENOMICSUnited StatesPublic CompanyChromium single-cell instruments and consumables,Visium spatial instruments and consumables,Xenium in situ instruments and consumables,
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious-disease diagnostics,Oncology and sexual & reproductive health assays,
    AGILENT TECHNOLOGIESUnited StatesPublic CompanyLife Sciences and Diagnostics (instruments, reagents, genomics, pathology, CDMO, biomolecular analysis),Agilent CrossLab (services, consumables, software, asset management),Applied Markets (GC, MS, spectroscopy, vacuum, remarketed instruments),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research and genomic tools),Diagnostics (clinical instruments and consumables),
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
    ADAPTIVE BIOTECHNOLOGIESUnited StatesPublic CompanyclonoSEQ MRD diagnostics,Life sciences research immunosequencing,Pharma and biotech drug discovery partnerships,
    PERSONALIS, INC.United StatesPublic CompanyPharma and biotech translational research / clinical trial services (ImmunoID NeXT and exome-based services),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related tests),

    ILLUMINA, INC.

    Illumina, Inc. is a United States-based public company founded in 1998 that employs 8,625 people. The company operates in the life sciences and genomics sector.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. It is a major provider of analytical instruments, reagents, and laboratory services.

    PACBIO

    PacBio is a United States-based public company founded in 2000 with 485 employees. The company specializes in DNA sequencing technology and solutions.

    OXFORD NANOPORE TECHNOLOGIES PLC

    Oxford Nanopore Technologies PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees. It develops nanopore-based DNA and RNA sequencing technologies.

    10X GENOMICS

    10X Genomics is a United States-based public company founded in 2012 with 1,178 employees. The company provides solutions for single-cell and spatial genomics analysis.

    QIAGEN

    QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It develops and manufactures molecular diagnostics and life sciences products.

    AGILENT TECHNOLOGIES

    Agilent Technologies is a United States-based public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. It operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

    TAKARA BIO INC.

    Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company develops and manufactures molecular biology reagents and biotechnology products.

    ADAPTIVE BIOTECHNOLOGIES

    Adaptive Biotechnologies is a United States-based public company founded in 2009 with 624 employees. The company develops immune-driven diagnostics and therapeutics using T-cell and B-cell receptor sequencing.

    PERSONALIS, INC.

    Personalis, Inc. is a United States-based public company founded in 2011 with 260 employees. The company offers precision medicine and genomic analysis services.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 149.3 Million · 9.3% wtd CAGR ·
    Asia Pacific
    ~USD 81.1 Million · 10.4% wtd CAGR ·
    Latin America
    ~USD 17 Million · 8.3% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 33.3 Million
    UKUSD 25.2 Million
    FranceUSD 13.2 Million
    ItalyUSD 6.4 Million
    SpainUSD 4.5 Million

    Country market size visualization

    Germany
    USD 33.3 Million
    UK
    USD 25.2 Million
    France
    USD 13.2 Million
    Italy
    USD 6.4 Million
    Spain
    USD 4.5 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for Europe ($62M in 2025, $99.5M in 2030) with country-level breakdowns for Germany, UK, France, Italy, and Spain to support strategic planning and investment decisions.
    • Competitive Landscape Intelligence : Understand Europe-specific competitive dynamics, key players, and market consolidation trends to identify partnership and acquisition opportunities within the region's growing immune sequencing ecosystem.
    • Clinical Adoption & Reimbursement Insights : Access detailed analysis of European clinical adoption rates, regulatory pathways, and reimbursement frameworks that influence market penetration and revenue potential across different healthcare systems.
    • Growth Driver Analysis : Identify Europe-specific growth catalysts including precision oncology demand, immunotherapy expansion, research funding trends, and healthcare digitalization initiatives shaping market trajectory.
    • Strategic Market Entry Planning : Leverage comprehensive European market segmentation, customer needs assessment, and regional expansion strategies to optimize market entry, product positioning, and go-to-market approaches.

    Frequently asked questions

    What is the current market size of immune repertoire sequencing in Europe?

    Europe's immune repertoire sequencing market is valued at $62.0 million in 2025, with expectations to grow to $99.5 million by 2030.

    What is the projected growth rate for immune repertoire sequencing in Europe?

    Europe's immune repertoire sequencing market is expected to grow at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2030.

    Which factors are driving growth in Europe's immune repertoire sequencing market?

    Europe's market growth is driven by advanced healthcare infrastructure, substantial R&D funding, regulatory support for genomic innovation, and increasing adoption in precision medicine and immunotherapy applications.

    How is Europe utilizing immune repertoire sequencing in clinical practice?

    Europe is integrating immune repertoire sequencing into diagnostic workflows for oncology, infectious disease management, and autoimmune disorder profiling, supported by clinical validation studies and healthcare system adoption.

    What is the forecast market size for immune repertoire sequencing in Europe by 2030?

    Europe's immune repertoire sequencing market is forecast to reach $99.5 million by 2030, representing significant expansion from the 2025 baseline of $62.0 million.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global IRS market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    The market for the companies offering IRS is arrived at by secondary data available through paid and unpaid sources, analyzing the product and service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global IRS market, which was validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global IRS market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, and experts from the supply side, such as C-level and D-level executives and managers. These interviews were conducted across major regions: North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

    The following is a breakdown of the primary respondents:

    Immune Repertoire Sequencing Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the IRS market was estimated and validated through multiple approaches, such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various market subsegments.

    • The research methodology used to estimate the market size includes the following:
    • The key players in the immune repertoire sequencing market have been identified through extensive primary and secondary research.
    • The revenues generated from the immune repertoire sequencing businesses of leading players in product and service offerings were determined separately through primary and secondary research.
    • The sum of the product and service market was used to arrive at the total IRS global market size, which was further segmented into various segments.
    • All percentage shares, splits, and breakdowns for respective market segments were determined using secondary sources and verified through primary sources.  
    Immune Repertoire Sequencing Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

    Market Definition

    Immune repertoire refers to the diverse collection of T-cell and B-cell receptors within the adaptive immune system, which enables pathogen recognition and targeted immune responses. The IRS market encompasses technologies, products, and services that analyze the diversity and functional dynamics of T-cell and B-cell receptor repertoires within the adaptive immune system.

    This market includes instruments, software, assays, kits, and reagents for immune receptor profiling, alongside presequencing, sequencing, and data analysis services that support research applications, drug discovery & development, and clinical diagnostics utilizing advanced methods such as NGS and PCR by various end users.

    Stakeholders

    • CDMOs & CROs
    • Pharmaceutical & Biopharmaceutical Companies
    • Academic & Research Institutes
    • Diagnostic Companies
    • Venture Capitalists & Investors
    • Market Research & Consulting Firms
    • Government & Regulatory Associations

    Report Objectives

    • To define, describe, and forecast the IRS market based on product, products technology, service workflow, application, product end user, service end user, and region.
    • To provide detailed information regarding the major factors influencing market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
    • To strategically analyze micromarkets concerning their growth trends, prospects, and contributions to the total IRS market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the revenue of market segments with respect to six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
    • To profile key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments in the IRS market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and R&D activities
    • To track and analyze the impact of AI/Gen AI on the IRS market
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and service excellence strategy

     

    Get the Full Immune Repertoire Sequencing Market Report

    Full forecast, segment splits, and company analysis for all Immune Repertoire Sequencing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status